Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company announced that Abilify (aripiprazole) received expanded indications in Bipolar I Disorder and Schizophrenia.
Abilify is now indicated for maintenance treatment of manic and mixed episodes associated with Bipolar I disorder with or without psychotic features in paediatric patients (aged 10-17) and maintenance treatment of Schizophrenia in adolescents (aged 13-17). In addition, Abilify is also granted an indication for adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with Bipolar I disorder with or without psychotic features in paediatric patients (aged 10-17).
The details can be read here.
No comments:
Post a Comment